Takeda Pharmaceutical Co Ltd - Mar 14, 2022 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
10%+ Owner
Signature
/s/ Amit Singh, Senior Vice President and Head of Treasury of Takeda Pharmaceutical Company Limited
Stock symbol
PHAT
Transactions as of
Mar 14, 2022
Transactions value $
-$342
Form type
4
Date filed
3/16/2022, 08:10 PM
Previous filing
Dec 9, 2021
Next filing
Apr 29, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Exercise of in-the-money or at-the-money derivative security $0 +7.36M +7359.3% $0.00 7.46M Mar 14, 2022 Direct F1
transaction PHAT Common Stock Sale -$342 -18 0% $19.00 7.46M Mar 14, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Warrants Exercise of in-the-money or at-the-money derivative security $0 -7.36M -100% $0.00* 0 Mar 14, 2022 Common Stock 7.36M $0.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 14, 2022, the Reporting Person exercised a Warrant to purchase 7,359,304 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $2.52 in lieu of a fractional share.